SEC Tracker
Get the app

Iovance Biotherapeutics IOVA

Iovance BIOtherapeutics announces trial results

Item 8.01 Other events

Form
8-K
Filed
Importance
Routine
  1. Updated results from Cohorts 1 and 2 of Phase 2 IOV-LUN-202 trial
  2. Biomarker-enriched precision TIL strategy for lifileucel in non-squamous NSCLC

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Iovance Biotherapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Elite Pharmaceuticals ELTP public float $534M, Sep 30, 2025
  2. Opko Health OPK public float $540M, Dec 31, 2025
  3. Savara SVRA public float $544M, Jun 30, 2025
  4. Xencor XNCR public float $556M, Jun 30, 2025
  5. Evolus EOLS public float $560M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.